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Summary  Cardiovascular  disease  is  still  the  main  cause  of  death  in  the  world,  and  coronary
artery disease  is  the  largest  contributor.  Screening  asymptomatic  individuals  for  coronary  artery
disease in  view  of  preventive  treatment  is  therefore  of  crucial  interest.  Apart  from  establisheddisease;
Coronary  artery
calcium  score;
Screening;
Prevention
risk scores  based  on  traditional  risk  factors  such  as  the  Framingham  or  SCORE  risk  scores,  new
biomarkers and  imaging  methods  have  emerged  (high-sensitivity  C-reactive  protein,  lipoprotein-
associated  phospholipase  A2  and  secretory  phospholipase  A2,  coronary  artery  calcium  score,
Abbreviations: ABI, ankle-brachial index; ACC, American College of Cardiology; AHA, American Heart Association; BARI-2D, bypass
angioplasty revascularization investigation 2 diabetes; CACS, coronary artery calcium score; CI, conﬁdence interval; CIMT, carotid intima-
media thickness; COURAGE, clinical outcomes utilizing revascularization and aggressive drug evaluation; ESC, European Society of Cardiology;
FRS, Framingham risk score; hs-CRP, high-sensitivity C-reactive protein; Lp-PLA2, lipoprotein-associated phospholipase A2; MESA, Multi-
Ethnic Study of Atherosclerosis.
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carotid  intima-media  thickness  and  ankle-brachial  index).  Their  added  value  on  top  of  the
classic risk  scores  varies  considerably  and  the  most  convincing  evidence  exists  for  coronary
artery calcium  score  in  intermediate-risk  asymptomatic  individuals.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  Les  maladies  cardiovasculaires  représentent  toujours  la  première  cause  de  mortalité
dans le  monde,  et  la  coronaropathie  en  constitue  la  majeure  partie.  Le  dépistage  de  la  maladie
coronaire  chez  les  sujets  asymptomatiques  dans  le  but  d’instaurer  un  traitement  préventif
présente donc  un  intérêt  majeur.  À  côté  des  scores  de  risque  établis  basés  sur  les  facteurs
de risque  traditionnels,  comme  le  score  de  Framingham  ou  la  méthode  SCORE,  de  nouveaux
biomarqueurs  ou  méthodes  d’imagerie  ont  fait  leur  apparition  (la  protéine  C-réactive  ultra-
sensible, la  phospholipase  A2  associée  aux  lipoprotéines  et  la  phospholipase  A2  sécrétoire,  le
score calcique,  l’épaisseur  intima-media  carotidienne  et  l’index  de  pression  systolique).  Leur
valeur ajoutée  aux  scores  de  risque  classiques  varie  fortement  en  fonction  du  marqueur  utilisé.
Les preuves  les  plus  solides  existent  pour  le  score  calcique  chez  les  sujets  asymptomatiques  à
risque intermédiaire.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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horonary heart disease: the leading cause
f  death worldwide
espite  an  important  reduction  in  cardiovascular  mortality
n  western  countries  [1,2],  cardiovascular  diseases  are  still
he  main  causes  of  mortality  in  the  world.  In  2010,  one  in
our  deaths  was  attributable  to  ischaemic  heart  disease  or
troke,  compared  to  one  in  ﬁve  in  1990  [3].  Likewise,  in
urope,  cardiovascular  diseases  were  responsible  for  more
han  half  of  deaths  in  women  and  42%  of  deaths  in  men,
ainly  due  to  coronary  heart  disease  [4].  Data  are  similar
n  low-income  countries,  with  more  than  12  million  deaths
elated  to  cardiovascular  causes  [5].
hy should we screen asymptomatic
ndividuals for cardiovascular disease?
therosclerosis  is  a  slowly  progressing  disease,  character-
zed  by  a  long  asymptomatic  period  of  several  decades.
ipid-rich  plaques  develop  in  the  arterial  vessel  walls  and
ay  be  revealed  by  typical  symptoms,  such  as  angina
ectoris  or  intermittent  claudication,  in  stable  patients.
owever,  the  disease  can  also  be  revealed  by  an  acute
vent,  such  as  an  acute  coronary  syndrome  or  stroke,  with-
ut  any  preceding  symptoms  and,  in  the  worst  case,  by
udden  death.  It  is  therefore  crucial  to  develop  a  screening
trategy  in  asymptomatic  individuals  before  potentially  fatal
vents  occur.
Cardiovascular  screening  in  asymptomatic  individuals
ims  at  the  identiﬁcation  of  intermediate-  or  high-risk
ndividuals.  The  objective  is  to  initiate  strategies  that
ould  reduce  their  incidence  of  ischaemic  events  (including
yocardial  infarction)  and  ultimately  cardiovascular  death.
ifferent  preventive  strategies  have  been  proposed.
o
cFirst,  cardiovascular  risk  can  be  reduced  by  optimal  risk
actor  management  and  lifestyle  changes.  Smoking  cessation
s  a  cornerstone  of  cardiovascular  disease  prevention  and
epresents  a public  health  problem  because  of  the  effect
f  passive  smoking  [6].  All  smokers  should  be  encouraged
o  quit  smoking  by  various  smoking-cessation  therapies  [7].
urthermore,  a  healthy  diet  and  regular  exercise  are  part
f  the  general  cardiovascular  prevention  measures  appli-
able  to  the  entire  population  [8,9].  Thus,  around  half
f  the  reduction  in  deaths  from  coronary  heart  disease  is
ttributable  to  better  management  of  cardiovascular  risk
actors  and  the  other  half  to  advances  in  medical  treatments
10].
Second,  a  preventive  medical  treatment  can  be  consid-
red  before  an  acute  cardiovascular  event  occurs.  However,
n  a low-risk  population,  further  risk  assessment  using  novel
iomarkers  is  not  cost-effective.  Furthermore,  in  a  high-risk
opulation,  pharmacological  treatment  is  usually  mandatory
or  the  majority  of  the  patients  and  further  risk  assessment
ill  not  change  this  strategy.  Conversely,  in  intermediate-
isk  individuals,  further  risk  assessment  by  novel  risk  markers
ould  reﬁne  cardiovascular  risk  and,  in  case  of  positive
creening,  indicate  preventive  pharmacological  treatment.
he  effectiveness  of  statin  treatment  for  primary  preven-
ion  in  a  population  with  cardiovascular  risk  factors  has
een  shown  in  large  meta-analyses  [11,12].  Statins  reduce
ortality  and  the  risk  of  major  cardiovascular  and  cere-
rovascular  events  in  people  without  known  cardiovascular
isease.  Similarly,  the  effect  of  blood  pressure  reduction  by
ntihypertensive  drugs  on  cardiovascular  disease  prevention
n  a  population  without  established  cardiovascular  disease
as  been  demonstrated  extensively,  irrespective  of  the  class
f  blood  pressure  lowering  drugs  used  [13].
Another,  more  invasive,  strategy  could  be  ‘preventive’
oronary  revascularization.  However,  most  acute  myocardial
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sScreening  in  asymptomatic  CAD  patients  
infarctions  evolve  from  mildly  obstructive  coronary  plaques,
which  are  not  addressed  by  angioplasty  in  stable  ischaemic
heart  disease  [14].  Thus,  preventive  revascularization  of
obstructive  coronary  stenosis  may  only  have  a  limited  effect
on  incident  myocardial  infarction  and  mortality  compared
with  medical  treatment.  This  has  been  demonstrated  by
two  large  trials  conducted  in  the  modern  era.  The  Clinical
Outcomes  Utilizing  Revascularization  and  Aggressive  Drug
Evaluation  (COURAGE)  trial  [15]  randomized  2287  patients
with  signiﬁcant  stable  coronary  artery  disease  and  objec-
tive  evidence  of  myocardial  ischaemia  to  optimal  medical
treatment,  alone  or  combined  with  angioplasty.  After  a
median  4.6-year  follow-up,  the  primary  outcome  of  death
from  any  cause  and  non-fatal  myocardial  infarction  was
not  signiﬁcantly  different  between  the  two  groups  (haz-
ard  ratio  [HR]  1.05,  95%  conﬁdence  interval  [CI]  0.87—1.27,
P  =  0.62).  Mortality  was  also  similar  in  the  two  groups  (HR
0.87,  95%  CI  0.65—1.16,  P  =  0.38).  Similarly,  bypass  angio-
plasty  revascularization  investigation  2  diabetes  (BARI-2D),
a  randomized  trial  in  2368  diabetic  patients  with  stable  coro-
nary  artery  disease,  showed  no  survival  difference  between
optimal  medical  treatment,  alone  (87.8%)  or  combined  with
angioplasty  (88.3%)  after  a  mean  of  5.3  years  of  follow-
up  (P  =  0.97)  [16].  A  recent  meta-analysis  on  this  subject,
published  in  2013  [17],  included  ﬁve  randomized  trials
comprised  of  5286  patients  with  stable  obstructive  coro-
nary  artery  disease,  of  whom  4064  had  proven  myocardial
ischaemia.  In  line  with  the  previous  results,  there  was  no
signiﬁcant  difference  between  optimal  medical  treatment
and  angioplasty  compared  to  optimal  medical  treatment
alone.
In  order  to  clarify  the  beneﬁts  of  coronary  revas-
cularization  in  stable  coronary  artery  disease,  a  large
randomized  trial  of  8000  patients,  the  International  Study
of  Comparative  Health  Effectiveness  with  Medical  and  Inva-
sive  Approaches  (ISCHEMIA)  (ClinicalTrials.gov  Identiﬁer:
NCT01471522),  is  currently  ongoing.  This  study  is  compar-
ing  an  initial  invasive  strategy  with  percutaneous  coronary
intervention  or  coronary  artery  bypass  surgery  along  with
optimal  medical  treatment  to  a  more  conservative  strat-
egy  with  optimal  medical  treatment  alone.  To  meet  the
inclusion  criteria,  all  patients  must  have  at  least  moder-
ate  ischaemia  (identiﬁed  on  an  ischaemia  test)  and  a  left
ventricular  ejection  fraction  >35%.  After  approximately  4
years  of  follow-up,  the  composite  primary  endpoint  of  car-
diovascular  death  or  myocardial  infarction  will  be  assessed.
This  trial  may  answer  some  of  the  questions  that  still  persist
on  the  real  beneﬁt  of  angioplasty  in  stable  ischaemic  heart
disease.
Cardiovascular risk prediction by
traditional risk factors
In  1948,  a  large,  ongoing,  longitudinal  observational  study
was  started  in  Framingham  (USA)  to  study  cardiovascular  dis-
ease.  Results  allowed  the  deﬁnition  of,  among  other  things,
the  well-known  Framingham  risk  score  (FRS).  Six  easily
available  items,  namely  sex,  age,  cigarette  smoking,  blood
pressure,  lipid  proﬁle  and  diabetes  mellitus,  allow  an  esti-
mation  of  the  relative  and  absolute  10-year  risk  for  coronary
heart  disease  [18].
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Cardiovascular  risk  is  different  across  populations  and  a
isk  score  is  only  applicable  in  the  population  it  was  val-
dated  in  [19].  In  fact,  in  Europe,  mortality  rates  differ
rom  North  to  South  and  from  East  to  West,  being  higher
n  the  Northeast  part  of  Europe.  This  geographical  gradient
eeds  to  be  taken  into  account  when  assessing  cardiovascu-
ar  risk  for  primary  prevention  [20].  Thus,  similarly  to  the
RS,  the  European  Society  of  Cardiology  (ESC)  developed
 risk  score  to  predict  the  10-year  risk  of  fatal  cardiovas-
ular  disease,  stratiﬁed  by  high-  or  low-risk  regions,  called
CORE  [21]  (Fig.  1 [22]).  The  ESC  guidelines  on  cardiovas-
ular  disease  prevention  in  clinical  practice  recommend  the
se  of  this  score  for  total  risk  estimation  in  asymptomatic
dults  without  evidence  of  cardiovascular  disease  [22]. Sim-
larly,  the  QRISK2  score,  an  updated  version  of  the  QRISK
core,  should  be  used  to  estimate  the  10-year  risk  of  cardio-
ascular  disease  of  the  population  in  the  United  Kingdom,
ecause  of  its  good  discriminative  and  calibration  properties
23].
These  risk  scores  are  not,  however,  perfect  prediction
ools—the  performance  of  the  SCORE  method  is  given  by  a
eceiver  operating  curve  area  of  0.81  (95%  CI  0.80—0.82)
n  high-risk  regions  and  0.74  (95%  CI  0.72—0.76)  in  low-risk
egions,  and  should  be  further  improved.  Intense  efforts
re  therefore  being  made  to  improve  their  discriminative
erformance,  by  the  inclusion  of  novel  biomarkers  or  devel-
ping  new  imaging  techniques.
ew methods for the assessment of
ardiovascular risk
everal  new  methods  for  risk  assessment,  using  either  imag-
ng  or  biomarkers,  have  been  developed  over  the  past
ecade,  with  variable  success.  We  review  below  the  evi-
ence  for  the  main  methods  in  the  context  of  the  recently
ublished  Guideline  on  the  Assessment  of  Cardiovascular
isk  from  the  American  College  of  Cardiology  (ACC)  and  the
merican  Heart  Association  (AHA)  [24].
nkle-brachial index
ne  of  the  simplest  and  most  cost-effective  markers  of
isk  is  the  ankle-brachial  index  (ABI).  The  result  is  avail-
ble  immediately  and  can  be  interpreted  at  the  patient’s
edside.  In  2008,  Fowkes  et  al.  [25]  reported,  in  a  meta-
nalysis  that  included  16  population  cohort  studies  with
8,294  healthy  individuals,  that  a  low  ABI  (≤  0.9)  was  asso-
iated  with  increased  10-year  cardiovascular  mortality  after
djusting  for  FRS  (HR  2.9,  95%  CI  2.3—3.7  for  men  and  HR
.0,  95%  CI  2.0—4.4  for  women).  Nevertheless,  the  increase
n  c-statistics,  compared  with  those  using  FRS  alone,  was
nly  modest  and  not  signiﬁcant  in  men  (from  0.646  to
.655),  but  increased  from  0.605  to  0.658  in  women.  More-
ver,  a  recent  double-blind  randomized  controlled  trial  that
creened  28,980  asymptomatic  participants  without  known
ardiovascular  disease  on  the  basis  of  ABI  for  treatment  with
ither  low-dose  aspirin  or  placebo  did  not  ﬁnd  any  improve-
ent  in  outcomes  after  a  mean  follow-up  of  8.2  years  [26].
uidelines  agree  that  ABI  has  a  class  IIb  (AHA/ACC)  or  class
678  P.  Degrell  et  al.
Figure 1. SCORE chart: 10-year risk of fatal cardiovascular disease in countries at low risk based on the following risk factors: age,
sex, smoking, systolic blood pressure and total cholesterol. CVD: cardiovascular disease. From Perk et al. [22] with permission. Low CVD
countries are Andorra, Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg,
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igh-sensitivity C-reactive protein
ne  of  the  most  studied  emerging  risk  factors  is  probably
igh-sensitivity  C-reactive  protein  (hs-CRP).  A  large  meta-
nalysis  [27]  has  shown  that  CRP  concentration  predicted
ascular  death  in  160,039  individuals  without  known  vascu-
ar  disease  after  adjustment  for  age  and  sex.  However,  it
redicted  non-vascular  death,  for  example  death  from  can-
er  or  respiratory  disease,  to  the  same  extent.  Thus,  the
ctual  value  of  higher  CRP  concentrations  in  the  individual
atient  setting  remains  unclear  and  the  recent  ESC  [22]  and
CC/AHA  [24]  guidelines  did  not  recommend  hs-CRP  mea-
urement  in  asymptomatic  low-  or  high-risk  individuals  (class
II,  level  B),  but  suggested  it  might  be  useful  for  reﬁning  the
isk  in  intermediate-risk  individuals  (class  IIb,  level  B).
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ipoprotein-associated phospholipase A2
ipoprotein-associated  phospholipase  A2  (Lp-PLA2),
n  enzyme  that  is  expressed  by  inﬂammatory  cells  in
therosclerotic  plaques,  plays  a  major  role  in  the  pro-
ression  of  the  disease  by  producing  pro-inﬂammatory
nd  pro-apoptotic  mediators  via  oxidized  phospholipids
ydrolysis.  The  result  is  a  sustained  inﬂammation  at  the
laque  level  with  an  expansion  of  the  necrotic  core.  In
006,  Folsom  et  al.  [28]  reported  a  series  of  case-cohort
tudies  including  15,792  participants  followed  up  for  5
ears  for  incident  coronary  heart  disease.  Several  novel
iomarkers  were  assessed  as  well  as  the  traditional  risk
actors.  Although  Lp-PLA2  was  associated  with  incident
oronary  heart  disease  after  established  risk  factor  adjust-
ent  (HR  1.17,  P  =  0.02),  the  c-statistic  increment  was  only
oderate,  from  0.774  to  0.780.  Another  study  indicated
hat  Lp-PLA2  predicted  survival  free  of  coronary  events  in
p
p
a
m
a
F
t
c
t
a
S
a
a
t
i
s
c
c
y
e
r
c
w
t
R
p
u
g
e
o
e
t
t
o
w
o
t
S
e
U
c
C
C
a
a
t
b
e
c
i
b
e
e
dScreening  in  asymptomatic  CAD  patients  
a  population  of  1077  individuals  without  known  coronary
heart  disease  [29].  Similarly,  Tsimikas  et  al.  [30]  published,
in  2009,  data  from  765  subjects  followed  up  prospectively
for  10  years.  They  showed  a  signiﬁcant  relationship  between
Lp-PLA2  activity  and  incident  cardiovascular  disease,  but
only  a  modest  increase  in  c-statistic,  from  0.717  to  0.737
(P  =  0.31),  compared  to  established  risk  factors  alone.  One
of  the  largest  meta-analyses  summarized  data  from  79,036
individuals  participating  in  32  prospective  studies  [31].  After
adjustment  for  conventional  risk  factors,  risk  ratios  for  inci-
dent  coronary  heart  disease  were  1.09  (95%  CI  1.02—1.16)
for  Lp-PLA2  mass  and  1.03  (95%  CI  0.95—1.12)  for  Lp-PLA2
activity.  Finally,  a  large  randomized,  double-blind  trial
assigned  15,828  patients  with  stable  coronary  heart  disease
to  receive  darapladib,  a  selective  oral  inhibitor  of  Lp-PLA2,
or  placebo  [32].  After  a  median  follow-up  of  3.7  years,
there  was  no  signiﬁcant  difference  in  the  primary  endpoint,
a  composite  of  cardiovascular  death,  myocardial  infarction
or  stroke  (HR  0.94,  95%  CI  0.85—1.03,  P  =  0.199).  These  data
meant  that  Lp-PLA2  assessment  was  only  recommended  for
patients  at  high  risk  for  a  recurrent  acute  atherothrombotic
event  in  the  2012  ESC  guidelines  [22]  (class  IIb,  level  B),
and  it  was  not  included  in  the  2013  AHA/ACC  guideline
[24].
Coronary artery calcium score
The  assessment  of  coronary  artery  calcium  by  ultrafast  com-
puted  tomography  and  its  quantiﬁcation  by  a  score  was  ﬁrst
described  by  Agatston  et  al.  [33]  in  1990.  A  coronary  artery
calciﬁcation  was  deﬁned  as  a  hyper-attenuating  lesion  >130
Hounsﬁeld  units  with  an  area  ≥1  mm2.  A  score  for  each
region  of  interest  is  calculated  by  multiplying  the  lesion  area
(mm2)  by  a  density  factor  (between  1  and  4).  The  total  coro-
nary  artery  calcium  score  (CACS)  is  determined  by  adding  up
each  of  these  scores  for  20  slices,  with  a  slice  thickness  of
3  mm.  Since  then,  several  other  scoring  systems  have  been
proposed:  the  volume  score  method  and  the  calcium  mass
score.  Two  methods  are  used  for  the  assessment:  electron
beam  computed  tomography  and,  more  recently,  multide-
tector  computed  tomography  [34].
In  2005,  Taylor  et  al.  [35]  published  data  from  a  non-
referred  cohort  of  2000  healthy  men  and  women  aged
between  40  and  50  years  old  and  with  a  3-year  follow-
up.  Incident  acute  coronary  syndromes  and  cardiac  death
occurred  in  0.16%  of  the  men  without  coronary  calcium  ver-
sus  1.95%  of  the  men  with  coronary  calcium  (P  <  0.0001).
This  risk  was  incremental  across  increasing  coronary  artery
calcium  tertiles  (HR  4.3  per  quartile,  P  =  0.036)  after  risk
factor  adjustment.  Likewise,  Detrano  et  al.  [36]  reported
an  increase  in  major  cardiac  events  across  different  calcium
score  categories,  in  6722  participants  of  different  ethnic
origins  without  known  coronary  artery  disease  at  baseline,
after  a  mean  follow-up  of  3.8  years  (P  <  0.001).  Raggi  et  al.
[37]  studied  the  prognostic  value  of  CACS  in  35,388  elderly
asymptomatic  participants  without  known  coronary  artery
disease  and  a  mean  of  5.8  years  of  follow-up.  Survival
decreased  across  age  deciles  and  with  higher  CACS  cate-
gories  (P  <  0.0001).  These  data  showed  a  relation  between
high  CACS  values  and  an  increasing  cardiovascular  disease
risk  in  healthy  individuals,  but  do  not  demonstrate  an  added
value  of  CACS  over  established  risk  factor  scores.
m
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In  2004,  Greenland  et  al.  [38]  evaluated  the  additional
rognostic  value  of  CACS  in  1312  asymptomatic  partici-
ants  without  known  coronary  heart  disease  or  diabetes
fter  7  years  of  follow-up.  Eighty-four  patients  experienced
yocardial  infarction  or  death  from  coronary  heart  disease,
nd  CACS  predicted  these  events  only  in  individuals  with  an
RS  >10%  (P  <  0.001),  supporting  its  value  for  risk  stratiﬁca-
ion  within  subjects  at  intermediate  risk.  Receiver  operating
urves  showed  an  increase  in  area  under  the  curve  —  and
herefore  in  diagnostic  performance  —  from  0.63  with  FRS
lone  to  0.68  with  FRS  in  combination  with  CACS  (P  <  0.001).
imilarly,  a  meta-analysis  that  included  nine  studies  evalu-
ted  the  value  of  adding  CACS  to  established  risk  factors  in
symptomatic  subjects  [39]. It  showed  an  improvement  in
he  c-statistic  from  0.05  to  0.13  and  a  net  reclassiﬁcation
mprovement  from  14  to  25%.
The  subgroup  deriving  the  highest  value  for  CACS  reclas-
iﬁcation  has  been  evaluated  in  a  large  population-based
ohort  of  5878  asymptomatic  participants  without  known
oronary  heart  disease  or  diabetes  (mean  follow-up  of  5.8
ears)  [40]. The  reclassiﬁcation  beneﬁt  after  adding  CACS  to
stablished  risk  factors  was  most  evident  in  intermediate-
isk  categories  (deﬁned  by  a  3—10%  5-year  risk  of  incident
oronary  heart  disease),  because  77%  of  the  participants
ere  classiﬁed  in  the  extreme  risk  categories,  compared
o  69%  with  FRS  alone.  These  data  were  conﬁrmed  in  the
otterdam  study  [41]  that  comprised  2028  asymptomatic
articipants  evaluated  after  a  median  of  9.2  years  of  follow-
p.  In  this  study,  52%  of  the  patients  of  the  intermediate-risk
roup  (10—20%  by  FRS)  were  reclassiﬁed  after  adding  CACS
valuation.  Finally,  Erbel  et  al.  [42]  published,  in  2010,  the
utcomes  of  4129  individuals  with  no  coronary  artery  dis-
ase  at  baseline.  The  net  reclassiﬁcation  improvement  for
he  intermediate-risk  group  (10—20%  according  to  FRS)  after
he  addition  of  CACS  was  21.7%  (P  =  0.0002);  the  receiver
perating  curve  increased  from  0.681  to  0.749  (P  = 0.003)
ith  CACS,  and  CACS  improved  prediction  of  coronary  death
r  non-fatal  myocardial  infarction  when  added  to  conven-
ional  risk  scoring.  A  10-year  follow-up  of  the  Multi-Ethnic
tudy  of  Atherosclerosis  (MESA)  cohort  has  shown  very  low
vent  rates  in  those  with  zero  coronary  artery  calcium  [43].
ltimately,  CACS  may  help  match  statin  therapy  to  absolute
ardiovascular  disease  risk  [44].
oronary artery calcium score limitations
ACS  is  assessed  by  computed  tomography,  which  uses  X-rays
nd  exposes  the  patient  to  ionizing  radiation.  The  aver-
ge  effective  dose  ranges  from  0.7  to  1.8  mSv,  around  10
imes  the  effective  dose  of  a chest  X-ray,  but  it  has  recently
een  shown  that  low-dose  scanning  (0.37  mSv)  can  be  as
ffective  as  the  standard  dose  [45].  However,  in  cardiovas-
ular  risk  assessment,  a  certain  proportion  of  the  screened
ndividuals  are  healthy  and  this  radiation  exposure  must
e  justiﬁed.  Kim  et  al.  [46]  studied,  in  2009,  the  lifetime
xcess  cancer  risk  due  to  radiation  exposure  from  a  single
xamination  at  the  age  of  40  and  showed  that  for  a  median
ose  of  2.3  mSv,  this  risk  reached  nine  cancers  per  100,000
en  and  28  cancers  per  100,000  women.  Another  issue  con-
erns  cost-effectiveness,  because  the  cost  of  a  computed
omography  examination  is  approximately  100  US$.  A  recent
ost-effectiveness  study  suggested  that  screening  with  CACS
680  
Figure 2. Receiver operator characteristic curves showing area
under the curve for A. incident coronary heart diseasea; and B.
incident cardiovascular diseaseb, in intermediate-risk MESA partici-
pants. From Yeboah et al. [50] with permission. aC-statistics for
FRS alone, 0.623; FRS plus coronary artery calcium, 0.784 (P <
0.001); FRS plus intima-media thickness, 0.652 (P = 0.01); FRS plus
ﬂow-mediated dilation, 0.639 (P = 0.06); FRS plus high-sensitivity
C-reactive protein, 0.640 (P = 0.03); FRS plus family history, 0.675
(P = 0.001); and FRS plus ankle-brachial index, 0.650 (P = 0.01).
bC-statistics for FRS alone, 0.623; FRS plus coronary artery cal-
cium, 0.784 (P < 0.001); FRS plus intima-media thickness, 0.652
(P = 0.01); FRS plus ﬂow-mediated dilation, 0.639 (P = 0.06); FRS
plus high-sensitivity C-reactive protein, 0.640 (P = 0.03); FRS plus
family history, 0.675 (P = 0.001); and FRS plus ankle-brachial index,
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n  intermediate-risk  men  is  superior  to  the  current  practice
47].
The  ESC  prevention  guidelines  [22]  state  that  CACS
should  be  considered’  in  intermediate-risk  asymptomatic
ndividuals  for  cardiovascular  risk  assessment  (class  IIa,  level
).  To  the  same  extent,  the  AHA/ACC  guideline  [24]  indicates
 class  IIb,  level  B  for  CACS  use  in  this  setting.
arotid intima-media thickness
ecent  evidence  suggests  that  carotid  intima-media  thick-
ess  (CIMT)  has  a  poor  added  value  when  combined  with  the
RS  to  reﬁne  cardiovascular  risk  assessment  in  asymptomatic
ndividuals.  A  recent  meta-analysis  pooled  data  from  14
opulation-based  cohorts  with  45,828  individuals  without
nown  cardiovascular  disease  [48].  Overall,  the  net  reclas-
iﬁcation  improvement  was  small  (0.8%,  95%  CI  0.1—1.6%),
ven  when  considering  only  intermediate-risk  individuals
3.6%,  95%  CI  2.7—4.6%).  Thus,  there  is  little  reclassiﬁca-
ion  beneﬁt  after  adding  CIMT  to  FRS  for  predicting  the
0-year  absolute  risk  for  myocardial  infarction  or  stroke,
ith  c-statistics  of  0.759  versus  0.757.  Furthermore,  CIMT
easurement  lacks  standardization  and  there  are  concerns
egarding  interobserver  variability  [49].  As  a  consequence,
he  AHA/ACC  guideline  [24]  advised  against  the  use  of  CIMT
n  this  setting  (class  III,  level  B).
hat is ﬁnally left of the new methods for
isk  assessment?
verall,  the  added  value  of  emerging  risk  markers  on  top
f  standard  risk  score  appears  limited.  A  large  head-to-
ead  comparison  of  six  novel  risk  markers  has  included
330  intermediate-risk  participants  without  diabetes  of
he  MESA  cohort  [50].  Intermediate  risk  was  deﬁned  by
—20%  risk  according  to  FRS,  and  the  primary  outcome
as  incident  coronary  heart  disease  deﬁned  as  myocardial
nfarction,  angina  followed  by  revascularization,  resusci-
ated  cardiac  arrest  or  death  from  coronary  heart  disease.
fter  a  median  7.6-year  follow-up,  CACS,  ABI,  hs-CRP  and
amily  history  were  independently  associated  with  incident
oronary  heart  disease  in  multivariable  analyses  (HR  2.60,
5%  CI  1.94—3.50;  HR  0.79,  95%  CI  0.66—0.95;  HR  1.28,
5%  CI  1.00—1.64  and  HR  2.18,  95%  CI  1.38—3.42,  respec-
ively).  CIMT  and  brachial  ﬂow-mediated  dilation  were  not
ssociated  with  incident  coronary  heart  disease  in  multivari-
ble  analyses  (HR  1.17,  95%  CI  0.95—1.45  and  HR  0.95,  95%
I  0.78—1.14,  respectively).  To  compare  the  added  value
f  each  marker  to  the  FRS,  areas  under  the  curve  were
alculated  for  each  of  them:  CACS  showed  the  biggest  incre-
ent  in  c-statistic,  from  0.623  to  0.784  (P  <  0.001).  The  ﬁve
ther  markers  showed  only  modest  increments  in  c-statistics
Fig.  2) [50].As  a  consequence,  their  systematic  use  is  currently
ot  recommended.  The  AHA/ACC  guideline  from  2013  [24]
tated  that  if,  after  quantitative  risk  assessment,  a  risk-
ased  treatment  decision  is  uncertain,  assessment  of  one
.650 (P = 0.01). MESA: Multi-Ethnic Study of Atherosclerosis; FRS:
ramingham risk score.
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[Screening  in  asymptomatic  CAD  patients  
or  more  of  the  four  markers  (family  history,  hs-CRP,  CACS,
ABI)  may  be  considered  to  inform  treatment  decision-making
(class  IIb,  level  B).  Current  ESC  guidelines  for  cardiovascular
disease  prevention  [22]  globally  agree  with  this  statement
and  provide  a  class  IIa,  level  B  recommendation  for  CACS,
ABI  and  CIMT  and  a  class  IIb,  level  B  recommendation  for
hs-CRP  and  Lp-PLA2  in  this  setting.
Conclusions
Preventive  treatment  of  coronary  artery  disease  is  effec-
tive  and  justiﬁes  screening  for  this  frequent  and  potentially
lethal  disease  in  asymptomatic  individuals.  The  major  part
of  cardiovascular  risk  assessment  can  be  readily  performed
using  simple  risk  scoring  systems  based  on  established
cardiovascular  risk  factors  and  requires  simple  biological
measurements  and  clinical  information.  The  added  value
of  new  clinical  (ABI),  biological  (hs-CRP  and  Lp-PLA2)  and
imaging  (CACS  and  CIMT)  risk  markers  is  limited  and  can  only
be  recommended  in  intermediate-risk  populations  in  order
to  further  reﬁne  their  cardiovascular  risk  and  potentially
change  their  treatment  strategy.  The  most  convincing  data
pertain  to  CACS,  but  we  should  keep  in  mind  the  costs  and
the  radiation  exposure  of  this  technique  and  remember  that
identiﬁcation  of  high-risk  patients  should  not  be  equated
with  an  indication  for  revascularization  in  otherwise  stable
asymptomatic  individuals.
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